Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-04-26
1995-08-22
Dentz, Bernard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514303, 544 48, 544105, 544236, 544277, 544350, 546118, 546121, A61K 31435, C07D47104
Patent
active
054440661
DESCRIPTION:
BRIEF SUMMARY
This application has been filed under 35 USC 371 based on PCT/Japan 92/01297 filed 10-6-1992.
FIELD OF INDUSTRIAL APPLICATION
The present invention relates to a thioformamide derivative useful as a drug.
BACKGROUND OF THE INVENTION AND PRIOR ART
Hypertension is known to be a disease which causes, as a complication, stroke or heart trouble which ranks high in the list of death cause in Japan, so that various studies have been made for the prevention and treatment thereof. The system for regulating the blood pressure is complicated and therefore, various types of antihypertensives have been used.
Such antihypertensives include diuretics, .beta.-blockers and ACE inhibitors. However, the diuretics cause, as an adverse effect, hyperuricemia, worsening of diabetes metlitus, induction of gouty attack or the like; the .beta.-blockers heart failure, bronchospasm or the like; and the ACE inhibitors dyspnea, cardioinihibition or the like. Thus, the antihypertensives of the prior art respectively cause serious adverse effects, particularly heart troubles, being disadvantageously difficult to use.
In Japan, the number of patients with coronary failures has reached the same level as that of the European and American countries with the westernization of the life style, and it is presumed that there are a considerably large number of patients with ischemic heart diseases (such as angina pectoris or myocardial infarction) including those induced from hypertension.
Although nitrite preparations and .beta.-blockers have been used as a preventive and therapeutic agent for angina pectoris, the nitrite preparations are disadvantageous in that they induce a tolerance in the patients and cause an adverse effect such as methemoglobinemia or ocular hypertension, while the .beta.-blockers cause, as described above, an adverse effect such as heart failure or bronchospasm. Therefore, discretion must be used in the administration of the drugs.
Meanwhile, the number of patients with asthma has recently increased, presumably owing to changes in the dietary habits or the worsening of the living environment by environmental pollution or the like.
Up to this time, .beta.-stimulants, methylxanthines, mast cell stabilizers and steroids have been used as preventive and therapeutic agents for asthma. However, the .beta.-stimulants cause, as an adverse effect, arrhythmia, hypertension, headache or the like; the methylxanthines gastrointestinal troubles or neuropathy; and the steroids diabetes mellitus or osteoporosis. Thus, these drugs sometimes cause serious adverse effects, so that discretion must be used in the administration thereof. Although, the mast cell stabilizers do not cause any serious adverse effect, they have disadvantages that the administration thereof to children or the aged is difficult, because they can be administered only as an inhalant, that they are inefficacious against serious asthma, that the efficacy thereof is poor, and that they cannot be used but as a preventive.
Under these circumstances, it has still been desired to develop a hypotensive or a preventive and therapeutic agent for heart diseases or asthma which has various mechanisms of action and is easily administrable by virtue of its higher safeness and superior to those of the prior art.
The inventors of the present invention have made intensive studies on compounds useful as such drugs. As a result of the studies, they have directed their attention to an ATP-sensitive potassium channel opening activity and have started studies for the purpose of finding a compound having such an activity.
As a result of these studies, the inventors of the present invention have found that thioformamide derivatives which will be described below can attain the above object. The present invention has been accomplished on the basis of this finding.
Although thioformamide derivatives having an activity as a drug are disclosed in, e.g., Japanese Patent Publication No. 59150/1990 and Japanese Patent Laid-Open Nos. 63260/1991, 289543/1990, 286659/1990, 211566/1989, 278/1990, 308
REFERENCES:
patent: 4959385 (1990-09-01), Cock et al.
patent: 5064843 (1991-11-01), Hart et al.
patent: 5104883 (1992-04-01), Palfreyman et al.
J. of Medicinal Chemistry, vol. 35, 1992, pp. 3613-3624 Brown et al "Syntheses and biological activity of trans(+-)-N-Methyl-2-3-pyridyl)-2-tetrahydrothiopyrancarbothioamide etc." p. 3613 and Table I.
Adachi Hideyuki
Hasegawa Takashi
Ishibashi Keiji
Kabasawa Yasuhiro
Katoh Hiroshi
Dentz Bernard
Eisai Co. Ltd.
LandOfFree
Thioformamide derivatives having hypotensive activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thioformamide derivatives having hypotensive activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thioformamide derivatives having hypotensive activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2142020